Latest Bioethics Stories
6.8% improvement in FEV1 versus placebo in high FENO subset representing half of treated patients BOULDER, Colo., March 3, 2014 /PRNewswire/ -- Array BioPharma Inc.
- Study Meets Primary and Both Key Secondary Endpoints - BRISBANE, Calif., Feb. 25, 2014 /PRNewswire/ -- InterMune, Inc.
MELBOURNE, Australia and NEW YORK, Feb.
Results from Alpha BRAIN™ Pilot Study to Be Presented at the International Neuropsychological Society Annual Conference Austin, Texas (PRWEB) February 14,
All proceeds from this special photo shoot will benefit homeless dogs and cats. Washington, DC (PRWEB) February 13, 2014
The nonprofit organization, Animals for Armed Forces® Foundation, appreciates the support of Julian Omidi and Dr. Michael Omidi and their charity Animal Support.
Company continues to expand its board and leadership team as it moves toward completion of its Phase 3 gene therapy program and advancement of the industry's deepest pipeline of gene-based medicines PHILADELPHIA,
DUBLIN, February 10, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/wlcf6t/mice_model_market) has announced the addition of the
Presentation to be Webcast Live on February 10, 2014 at 3 PM EST PRINCETON, N.J., Feb. 5, 2014 /PRNewswire/ -- Soligenix, Inc.
The OncoMouse or Harvard Mouse is a type of laboratory mouse that has been genetically modified utilizing modification designed by Philip Leder and Timothy A. Stewart, of Harvard University, to carry a certain gene called an activated oncogene. The activated oncogene considerably increases the mouse’s vulnerability to cancer, therefore making the mouse suitable for cancer research. The rights to the invention were owned by DuPont until recently. The USPTO found that the patent expired in...
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.
More Images (1 images) »